-
-
-
Popular Articles
-
Biopharmaceutical Companieses in the News
-
Biotechnology Companies in the News
-
Hospital or Medical Research Centers in the News
-
Informatics Companies in the News
-
Non-Profit Organizations in the News
-
Organizations in the News
-
Tools Companies in the News
-
SPONSORED LINKS
Optimize Trial Design through Simulation Modeling - Webinar
White Paper: Improving Drug Manufacturing Quality with a SDMS
Exemplar Biomarker Discovery – Your Complete Solution for Personalized Medicine
Free Webinar - Running Adaptive Clinical Trials: Myth and Reality
Free Webinar on Compliance and Patient Data –Meeting the Needs!
Grid Engine @ Univa: 200 improvements and counting
Analyze, compare & visualize NGS datasets with CLC bio's intuitive platform
Protect Your Kingdom - RSA Conf 2012
Free whitepaper: Understanding Legal Issues Surrounding Electronic Lab Notebook Records
ClearTrial Named a Gartner "Cool Vendor in Life Sciences, 2011"
Data Repository, ELN, & Laboratory Execution - Waters® NuGenesis® SDMS
Discover Timaeus 5, an on-demand eClinical platform for Study Design Through Reporting.
Free WhitePaper: Increase Innovation with Improved Scientific Data Management
Biotech 2010 Life Sciences: Adapting for Success
Online community for pioneers in next-gen sequencing & bioinformatics
Barnett International: Training Strategy and Consulting
Competitive Analysis & Insight with Concise Research Reports
Current & Innovative NGS Technologies, Services & Markets
Next Generation Mass Spectrometry
New Trends in Preventive and Therapeutic Vaccines
Next-Generation Sequencing Technologies: Applications and Markets
-
-
How Does Big Pharma Boost Its Returns?
Explore Fool.com (Feb 19 2012) Electronic Data Capture (EDC)
Break it down with the DuPont Formula.
Comment Mentions: FDA GlaxkSmithKline plc Novartis International AG
-
Deadly bird flu studies to stay secret for now: WHO
Explore reuters.com (Feb 17 2012) Electronic Data Capture (EDC)
GENEVA/LONDON (Reuters) - Two studies showing how scientists mutated the H5N1 bird flu virus into a form that could cause a deadly human pandemic will be published only after experts fully assess the risks, the World Health Organization (WHO) said on Friday.
-
Why Bristol-Myers Squibb Could Break Out This Year
Explore The Motley Fool (Feb 15 2012) Electronic Data Capture (EDC) , Trial Design and Logistics
Why Bristol-Myers Squibb Could Break Out This Year
Comment Mentions: FDA Merck & Co Inc Bristol-Myers Squibb
-
19 Clinical Trials Aren't Enough
Explore Fool.com (Jan 20 2012) Electronic Data Capture (EDC) , Trial Design and Logistics
The FDA rejects Bristol-Myers and AstraZeneca's dapagliflozin.
Comment Mentions: FDA AstraZeneca The Food and Drug Administration
-
Medidata: Integrating Infrastructure for Clinical Trials
Explore Bio-IT World (Jan 18 2012) Electronic Data Capture (EDC) , Regulatory Issues & Drug Safety , Trial Design and Logistics
Bio-IT World | Glen de Vries thought he would be teaching biology or chemistry in college, but somewhere en route to a satisfying career in academic research, he got distracted. Bio•IT World chief editor Kevin Davies spoke to de Vries about the progress of Medidata and the state of e-clinical technology in general.
Comment Mentions: SAP Kevin Davies, Ph.D. Medidata
-
Perceptive Informatics DataLabs EDC Solution Implemented by 15 of the top Global Biopharmaceutical Companies
Explore Industry (Dec 30 2011) Electronic Data Capture (EDC)
News Brief | This latest milestone was preceded by an independent report from Industry Standard Research, which ranked the DataLabs EDC solution the highest in overall satisfaction among EDC solutions in a survey of principal investigators and site coordinators.
Comment Mentions: Parexel International Perceptive Informatics PAREXEL International PAREXEL International Corporation
-
Whoa! These Stocks Spread Some Holiday Cheer
Explore Fool.com (Dec 27 2011) Electronic Data Capture (EDC)
These stocks just took off, but are they about to make a return trip to Earth?
Comment Mentions: FDA Bristol-Myers Squibb
-
The News That Moved the Market Today
Explore Fool.com (Dec 27 2011) Electronic Data Capture (EDC)
Breaking down the market.
-
Venezuela offers free removal of PIP breast implants
Explore reuters.com (Dec 27 2011) Electronic Data Capture (EDC)
CARACAS (Reuters) - Venezuela is offering women the free removal of breast implants made by a bankrupt French company that used industrial silicone to make cheap prostheses linked to health risks.
-
Bulk of company's implants used subpar silicone
Explore reuters.com (Dec 27 2011) Electronic Data Capture (EDC) , Trial Design and Logistics
TOULON, France (Reuters) - The lawyer for the French company at the heart of an escalating global breast implant scare told Reuters on Tuesday that most of the protheses sold by the firm since 1991 were produced using a non-approved silicone.
-
Many seriously ill get too much care: docs, nurses
Explore reuters.com (Dec 27 2011) Electronic Data Capture (EDC)
NEW YORK (Reuters Health) - A third of doctors working in intensive care units (ICUs) believe one or more of their patients is getting inappropriate care, with slightly fewer nurses sharing the sentiment, a European poll shows.
Comment Mentions: FDA American Medical Association
-
2011 No Dreamboat for MannKind
Explore Fool.com (Dec 27 2011) Electronic Data Capture (EDC) , Regulatory Issues & Drug Safety , Trial Design and Logistics
An FDA rejection and a long wait is a bad combination.
Comment Mentions: FDA Pfizer Inc Novo Nordisk A/S
-
Exelixis 2011: Not What the Doctor Ordered
Explore Fool.com (Dec 27 2011) Electronic Data Capture (EDC)
A tale of an inability to get a Special Protocol Assessment from the FDA.
Comment Mentions: FDA AstraZeneca Dendreon
-
FDA moves forward with new Repros Therapeutics therapy
Explore Business News (Dec 27 2011) eClinical Products , Electronic Data Capture (EDC)
The U.S. Food and Drug Administration is in agreement with Repros Therapeutics Inc. (Nasdaq:RPRX) on how to move forward in approaching the development of a new testosterone production therapy, according to a release from the company on Tuesday. The therapy, Androxal, produces testosterone levels in the normal range for men while helping them maintain sperm count. Repros Therapeutics President and CEO Joseph Podolski said products currently on the market that treat testosterone deficiencies typically decrease sperm count...
-
Mylan wins OK for anti-seizure generic drug
Explore Business News (Dec 27 2011) eClinical Products , Electronic Data Capture (EDC)
Southpointe-based Mylan Inc. has received the go-ahead from the U.S. Food and Drug Administration to market a generic Keppra XR extended release tablet to treat epileptic seizures. The FDA approval to Mylan Pharmaceuticals, a unit of Mylan Inc. (Nasdaq: MYL), is under the abbreviated new-drug application/first-to-file program. The product name is Levetiracetam Extended-Release (ER) Tablets, 500 mg and 750 mg, the generic of UCB's Keppra XR. There were sales of $162.8 million for the year ended Sept...
-
1-15 of 85 // 1 2 3 4 5 6 »
-
-







Recent Comments
HuffmanDAWN28 » U.S. cancer drugs shortage has doctors scrambling
Every body understands that our life is very expensive, however different people require cash for ...
HuffmanDAWN28 » U.S. cancer drugs shortage has doctors scrambling
I received my first business loans when I was 32 and that supported my family ...
See all recent comments